JAZZ

Jazz Pharmaceuticals Plc - Q1 2010 Filing Summary

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended March 31, 2010. Jazz Pharmaceuticals is a specialty pharmaceutical company focused on neurology, psychiatry, and pain management. The company markets two primary products: Xyrem (sodium oxybate) for narcolepsy and Luvox CR (fluvoxamine maleate) for OCD and social anxiety disorder. The company is awaiting FDA approval for its late-stage product candidate, JZP-6 (sodium oxybate) for fibromyalgia, with a Prescription Drug User Fee Act action date of October 11, 2010.

Key Financial Metrics

Margins: Gross margin on product sales improved to approximately 91.6% in Q1 2010 compared to 90.9% in Q1 2009, driven by price increases.

Material Changes vs. Prior Period

• Revenue Growth: Total revenues increased 59% year-over-year, driven primarily by a 61% increase in net product sales. Xyrem sales rose 62% (due to price increases and volume growth), and Luvox CR sales rose 54% (driven by volume).
• Profitability Turnaround: The company reported a net income of $1.5 million in Q1 2010, a significant improvement from a net loss of $13.0 million in Q1 2009. This was achieved through revenue growth and a 46% reduction in R&D expenses.
• Expense Management: R&D expenses decreased to $6.2 million from $11.4 million as the company shifted focus from active Phase III trials to NDA prosecution for JZP-6. SG&A expenses increased 18% to $16.8 million due to pre-launch planning for JZP-6.
• Debt Reduction: The company repaid $3.0 million in principal on its Senior Secured Notes and reduced its revolving line of credit balance by $1.6 million.

Outlook, Risks, and Contingencies

• Liquidity and Capital Needs: Management believes existing cash, operating cash flow, and the revolving credit line are sufficient to fund operations through March 31, 2011. However, the company explicitly states it does not expect current resources to cover the launch of JZP-6 (if approved), Luvox CR Phase IV trial commitments, or the full repayment of Senior Notes maturing in June 2011. Additional funding via equity, partnerships, or debt will be required.
• Debt Obligations: Significant principal payments on Senior Notes are due: $6.0M (June 2010), $9.0M (Sept 2010), $10.0M (Dec 2010), and $12.0M (March 2011), with the remaining ~$79.5M due June 24, 2011.
• Supply Chain Risk: Lonza, the sole supplier of sodium oxybate (active ingredient in Xyrem and JZP-6), is closing its plant. The company has signed a new supplier agreement, but FDA approval and DEA quota allocation for the new supplier are pending and critical for uninterrupted supply.
• Regulatory and Legal:
  • JZP-6: FDA review is ongoing; approval is not guaranteed.
  • Luvox CR: The company is litigating against Actavis and Anchen regarding generic ANDA filings. Additionally, the company submitted a labeling supplement to remove the Social Anxiety Disorder (SAD) indication to potentially avoid costly Phase IV trial commitments.
  • Healthcare Reform: The Patient Protection and Affordable Care Act is expected to increase rebate costs by approximately $1.0 million for the remainder of 2010.

Investor Verification Checklist

• Verify the status of the DEA quota for the new sodium oxybate supplier and the timeline for FDA approval of the new manufacturing site.
• Confirm the FDA decision timeline for the JZP-6 NDA (action date Oct 11, 2010) and the potential impact of a REMS program on commercialization.
• Monitor the outcome of the litigation regarding generic Luvox CR and the FDA's decision on the labeling supplement to remove the SAD indication.
• Assess the company's ability to raise capital or secure partnerships to fund the June 2011 debt maturity and JZP-6 launch costs.
• Review the impact of the Healthcare Reform Act on net product sales and rebate liabilities in subsequent quarters.